All News
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
Read Article
Spondyloarthritis and COVID-19
There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question.
Read Article
Key Psoriatic Arthritis topics and updates at EULAR 2022
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA). Here are my top picks from this year's meeting.
Read Article
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/Y6FVcjHGr2 https://t.co/eTYedqiScE
Links:
Dr. John Cush RheumNow ( View Tweet)
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT
Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p
Links:
Dr. John Cush RheumNow ( View Tweet)
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Robert B Chao, MD doctorRBC ( View Tweet)
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
Richard Conway RichardPAConway ( View Tweet)
Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ
Richard Conway RichardPAConway ( View Tweet)
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
Richard Conway RichardPAConway ( View Tweet)
Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj
Richard Conway RichardPAConway ( View Tweet)
High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU
Janet Pope Janetbirdope ( View Tweet)
Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
Richard Conway RichardPAConway ( View Tweet)
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
Richard Conway RichardPAConway ( View Tweet)
Tillett et al. Baseline characteristics and achievement of MDA at week 24 with IL23i guselkumab in bDMARD experienced patients. Pattern of joint (wrist vs shoulder/hand) and skin (scalp vs hand/foot) involvement, as well as male sex, predictive @RheumNow #EULAR2022 POS1051 https://t.co/lHOTgMWgMA
Richard Conway RichardPAConway ( View Tweet)
Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt
Richard Conway RichardPAConway ( View Tweet)
Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8
Richard Conway RichardPAConway ( View Tweet)
Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3
Richard Conway RichardPAConway ( View Tweet)
Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
Richard Conway RichardPAConway ( View Tweet)
Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly
Stronger rationale that diet may be really important in some patients
#EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV
David Liew drdavidliew ( View Tweet)
Zabotti et al. IL23i guselkumab. Machine learning identified clusters of MDA response @RheumNow #EULAR2022 OP0259 https://t.co/67tfuADxLs https://t.co/33Y5m37K3y
Links:
Richard Conway RichardPAConway ( View Tweet)
